Commissions

Quote






I know two that went to competitive companies and guess what? Nothing has been done other than the initial scare tactic letter. Trust me, if you know them Im sure they would politely walk thru the steps and confirm nothing has been done.
 
























That is a really dumb comment and not true at all.

From the last earnings call

As of December 31, 2014, total cash was $20.0 million, a decrease of $2.1 million compared to December 31, 2013. The significant uses of cash during the year were $5.7 million for the purchase of Mednet, $8.0 million for the purchase of BMS and $0.4 million for the purchase of RadCore. The Company also used $12.8 million of cash for capital purchases, primarily related to medical devices in the Patient Services and Research Services segments for use in ongoing operations and the investment in internally developed software.

In the fourth quarter, the Company entered into a credit agreement with General Electric Capital Corporation for a five-year $25.0 million term loan with an additional $15.0 million revolver that remains undrawn. This new agreement will provide additional financing capacity as opportunities arise to accelerate the Company's strategic plan and for the consolidation and repayment of $17.4 million of existing debt. This debt is subject to standard financial covenants including a minimum fixed charge ratio and a maximum leverage ratio.

restructuring and other nonrecurring charges which includes the $6.4 million estimate for the settlement with the Department of Justice.

Plenty of cash to pay the fine so stop making up excuses in your little mind
 












Anonymous said:
That is a really dumb comment and not true at all.

From the last earnings call

As of December 31, 2014, total cash was $20.0 million, a decrease of $2.1 million compared to December 31, 2013. The significant uses of cash during the year were $5.7 million for the purchase of Mednet, $8.0 million for the purchase of BMS and $0.4 million for the purchase of RadCore. The Company also used $12.8 million of cash for capital purchases, primarily related to medical devices in the Patient Services and Research Services segments for use in ongoing operations and the investment in internally developed software.

In the fourth quarter, the Company entered into a credit agreement with General Electric Capital Corporation for a five-year $25.0 million term loan with an additional $15.0 million revolver that remains undrawn. This new agreement will provide additional financing capacity as opportunities arise to accelerate the Company's strategic plan and for the consolidation and repayment of $17.4 million of existing debt. This debt is subject to standard financial covenants including a minimum fixed charge ratio and a maximum leverage ratio.

restructuring and other nonrecurring charges which includes the $6.4 million estimate for the settlement with the Department of Justice.

Plenty of cash to pay the fine so stop making up excuses in your little mind
Click to expand...

FACT: We burned up all of cash. No more thanks to this settlement and great acquisitions.

FACT: Using ECAT as inventory when we used to laugh at ECAT and the former competition

FACT: Lots of good people have left the company, and most of those I talk to are looking and unhappy.

No excuses, unravelling all by itself...
 






Anonymous said:
No device that comes out of this space will ever be a game changer if you really know this market and good luck with ecardio with a total comp of 80 to 100 a year
Click to expand...

A total comp of 80-100 at Ecardio? You are waaaaay off my friend.
Do you have any idea what a 1099 stands for? The very bottom reps make 80-100 and are probably new reps. There is no paltry salary and a bonus plan that is ureachable like the competitors. This is an earn what you can position with no cap. What's not to like?
 












Preventice & eCardio merge. They become part of Merck's Global Health Innovations fund with $200M available to them; why would Merck invest that kind of money if there aren't some new innovations/programs coming down the pipeline that make sense?
 






Big pharma has-been is just looking for ways to stay relevant and will fail miserably in this space just like MDT has. The backorder will be over soon and those who have stayed loyal will be rewarded with new opportunities increased revenue. Have you ever known of a company that didn't have its ups and downs? CN is no different and we have always come out of the down times stronger and more energized. Let the weak and the scared run off to what they think looks like greener pastures - that grass will dry out and turn brown just a quickly.
 












Shouldn't we be getting our Q2 forecasts soon? Oh wait, I heard LW had a hangnail that got infected so now we won't get them on time as usual - I think they are shooting for the Friday before Memorial Day
 










































Top Bottom
Back
Quote